SAN DIEGO, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 8th Annual OneMedForum 2015 on Tuesday, January 13 at 2:40 PM PT at the Marriot Marquis Hotel in San Francisco.
Details of the presentation are as follows:
Event: 8th Annual OneMedForum
Date: Tuesday, January 13, 2015
Time: 2:40 PM PT
Place: Marriot Marquis Hotel (San Francisco, CA)
About Biocept, Inc.
Biocept, Inc., headquartered in San Diego, California, is a commercial stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BRTM test for breast cancer and OncoCEE-LUTM for lung cancer and plans to introduce additional biomarker tests for breast, lung, colorectal, prostate and other solid tumors based on its proprietary technology platforms.
CONTACT: Investor Contact: The Ruth Group David Burke (646) 536-7009 firstname.lastname@example.org